CoChat

Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)

Open access
Jäger, Michael, Schoberth, Alexandra, Ruf, Peter, Hess, Juergen, Hennig, Michael, Schmalfeldt, Barbara, Wimberger, Pauline, Ströhlein, Michael, Theissen, Bettina, Heiss, Markus M., Lindhofer, Horst · 2012 · Cancer Research
Cited by 117

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Patients with malignant ascites secondary to primary carcinomas benefit from intraperitoneal therapy with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). Here, we report the analysis of peritoneal fluid samples from 258 patients with malignant ascites randomized to catumaxomab or control groups to investigate the molecular effects of catumaxomab treatment. In the catumaxomab group, tumor cell numbers and peritoneal levels of VEGF decreased, whereas the activation status of CD4+ and CD8+ T-cell populations increased more than two-fold after treatment. Notably, CD133+/EpCAM+ cancer stem cells vanished from the catumaxomab samples but not from the control samples. In vitro investigations indicated that catumaxomab eliminated tumor cells in a manner associated with release of proinflammatory Th1 cytokines. Together, our findings show that catumaxomab therapy activates peritoneal T cells and eliminates EpCAM+ tumor cells, establishing a molecular and cellular basis to understand in vivo efficacy within the immunosuppressed malignant ascites tissue microenvironment. Cancer Res; 72(1); 24–32. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-2235

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 117

Metadata

Authors
Jäger, M., Schoberth, A., Ruf, P., Hess, J., Hennig, M., Schmalfeldt, B., Wimberger, P., Ströhlein, M., Theissen, B., Heiss, M. M., & Lindhofer, H.
Venue
Cancer Research
Published
2012-01-01
Volume
72
Issue
1
Pages
24-32
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1981910809
Cited by
117
References
3
FWCI
12.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3). https://app.cochat.ai/papers/10.1158/0008-5472.can-11-2235
The paper
Jäger, M., Schoberth, A., Ruf, P., Hess, J., Hennig, M., Schmalfeldt, B., Wimberger, P., Ströhlein, M., Theissen, B., Heiss, M. M., & Lindhofer, H. (2012). Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3). Cancer Research. https://doi.org/10.1158/0008-5472.can-11-2235

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.